Puma regains China rights to Nerlynx and amends deal with Fabre
Pierre Fabre pens oncology pact with atomic energy spinout | Fierce Biotech
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma and CANBridge cancel licensing deal for $20m
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies | Pierre Fabre Pharma Norden AB
Pierre Fabre and ValenzaBio collaborate on anti-IGF-1R antibody for TE
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in
Pierre Fabre & NERLYNX commercialisation | Nerlynx
Pierre Fabre étend ses droits sur le Nerlynx de Puma Biotechnology
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
Blue March: Pierre Fabre supports colorectal cancer awareness month
Puma Biotechnology | Evaluate
Puma licences breast cancer therapy Nerlynx to Pierre Fabre in Europe
CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration | Business Wire
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma regains China rights to Nerlynx and amends deal with Fabre
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
Partners of the Pierre Fabre Group: from health to beauty
